• Subjects must meet all the following criteria to be enrolled in this study:

• Age ≥18 years at the time of consent.

• Written informed consent in accordance with national, local, and institutional guidelines obtained prior to any study procedures. (Screening assessments performed prior to informed consent but within the 28-day screening window are acceptable for inclusion purposes).

• Subjects must have histologically confirmed diagnosis of one of the following tumors: triple negative adenocarcinoma of the breast (human epidermal growth factor receptor 2 negative, estrogen receptor negative and progesterone receptor negative \[HER2-/ER-/PR-\]), adenocarcinoma of the colon or rectum, hepatocellular carcinoma (HCC), osteosarcoma, epithelial ovarian cancer, malignant melanoma, non-small cell lung cancer (NSCLC), or gastric cancer. Documentation of the diagnosis with the original pathology report, or a recent biopsy, is required.

• Subjects must have relapsed disease or refractory disease. Subjects must have received, completed, or become intolerant of prior standard of care therapies or are not expected to derive any clinical benefit from standard of care therapies.

• Subjects with Ovarian cancer must have received at least one prior standard of care for their relapsed or refractory disease, which must include a platinum-based regimen.

• Subjects agree to provide fresh tumor tissue that has not been previously irradiated. If biopsy procedure is not safe to perform, then archival tumor tissue (20 slides or a tissue block) can be submitted.

• Subjects must have iRECIST evaluable disease using computed tomography (CT) or magnetic resonance imaging (MRI) with IV contrast, with at least one measurable target lesion.

• Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

• Subjects are expected to have a life expectancy of at least 12 weeks from the time of enrollment.

⁃ Adequate hematologic function at the time of screening, defined as: absolute lymphocyte count (ALC) \>500 cells/mm3, absolute neutrophil count (ANC) \>750 cells/mm3, hemoglobin \>8 g/dL, and platelet count \>50,000 cells/mm3. For subjects enrolling into the LDC cohorts, the criteria are defined as: ALC\>500 cells/mm3, ANC\>1000 cells/mm3, hemoglobin\>8g/dL, and platelet count\>100,000 cells/mm3.

⁃ a. Hemoglobin and platelet count thresholds must be achievable without transfusion of red blood cells or platelets, or use of growth factors administered within two weeks.

⁃ Adequate organ function, defined as:

∙ Renal function: serum creatinine \<1.5x institutional upper limit of normal (ULN) or calculated creatinine clearance \>50 mL/min.

‣ Adequate hepatic function: total bilirubin ≤1.5x institutional ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x institutional ULN, unless liver metastases are present, in which case it must be ≤5x ULN; International Normalized Ratio (INR) ≤1.5. For subjects with HCC, adequate hepatic function is defined as: total bilirubin ≤3x institutional upper limit of normal, AST/ALT ≤5x institutional ULN, INR ≤1.7, Child-Turcotte-Pugh score \<8.

⁃ Women of childbearing potential (defined as all subjects physiologically capable of becoming pregnant) must have negative serum ß-human chorionic gonadotropin (hCG) or urine pregnancy test.

⁃ Women of childbearing potential must agree to use highly effective methods of contraception throughout the study and for six months after the last dose of CRX100.

⁃ Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method throughout the study and for six months after the last dose of CRX100.

⁃ Subjects must be willing and able to comply with all study procedures, requirements, and follow-up examinations.